IL299896A - Methods for thermoforming polynucleotides into reduced sizes of lipid nanoparticles and their new formulation - Google Patents
Methods for thermoforming polynucleotides into reduced sizes of lipid nanoparticles and their new formulationInfo
- Publication number
- IL299896A IL299896A IL299896A IL29989623A IL299896A IL 299896 A IL299896 A IL 299896A IL 299896 A IL299896 A IL 299896A IL 29989623 A IL29989623 A IL 29989623A IL 299896 A IL299896 A IL 299896A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- lipid nanoparticles
- novel formulation
- reduced sizes
- polynucleotides
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053274P | 2020-07-17 | 2020-07-17 | |
| US202163194620P | 2021-05-28 | 2021-05-28 | |
| PCT/US2021/042033 WO2022016089A2 (en) | 2020-07-17 | 2021-07-16 | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299896A true IL299896A (en) | 2023-03-01 |
Family
ID=79555025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299896A IL299896A (en) | 2020-07-17 | 2021-07-16 | Methods for thermoforming polynucleotides into reduced sizes of lipid nanoparticles and their new formulation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230320993A1 (https=) |
| EP (1) | EP4181948A4 (https=) |
| JP (1) | JP2023534043A (https=) |
| KR (1) | KR20230052895A (https=) |
| CN (1) | CN116437964A (https=) |
| AU (1) | AU2021307952A1 (https=) |
| CA (1) | CA3186033A1 (https=) |
| IL (1) | IL299896A (https=) |
| MX (1) | MX2023000806A (https=) |
| WO (1) | WO2022016089A2 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| JP2020500150A (ja) | 2016-09-23 | 2020-01-09 | デューク ユニバーシティ | 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド |
| WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| US12594347B2 (en) | 2018-09-07 | 2026-04-07 | Duke University | Nanoparticulate drug delivery systems |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| JP7746280B2 (ja) | 2020-03-27 | 2025-09-30 | ジェネレーション バイオ カンパニー | 新規脂質及びそれらのナノ粒子組成物 |
| BR112023021504A2 (pt) * | 2021-04-20 | 2023-12-19 | Generation Bio Co | Lipídios catiônicos e composições dos mesmos |
| EP4310071A4 (en) * | 2021-05-28 | 2024-11-20 | Beijing Tricisionbio Therapeutics Inc. | LIPID COMPOUND AND USE THEREOF IN THE ADMINISTRATION OF NUCLEIC ACID |
| AU2022291742A1 (en) * | 2021-06-14 | 2023-12-21 | Generation Bio Co. | Cationic lipids and compositions thereof |
| US20250281596A1 (en) * | 2021-09-28 | 2025-09-11 | Seqirus Inc. | Ionizable cationic compound |
| CN118201605A (zh) * | 2021-10-25 | 2024-06-14 | 杜克大学 | 基于poegma的脂质纳米粒子 |
| WO2023190166A1 (ja) * | 2022-03-28 | 2023-10-05 | 日油株式会社 | ジスルフィド結合を有するカチオン性脂質、これを含む脂質膜構造体、これらのいずれかを含む核酸導入剤及び医薬品組成物、核酸を細胞又は標的細胞内へ導入する方法、及び細胞医薬品の製造方法 |
| CN114685784B (zh) * | 2022-04-26 | 2023-09-15 | 北京清科胜因生物科技有限公司 | 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 |
| EP4536197A1 (en) * | 2022-06-07 | 2025-04-16 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| CN115105584B (zh) * | 2022-06-28 | 2023-03-31 | 长春生物制品研究所有限责任公司 | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 |
| WO2024037577A1 (en) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
| US20240150306A1 (en) * | 2022-09-27 | 2024-05-09 | Reinvigoron Theratech, Inc. | Compounds with cleavable disulfide moieties |
| CN120091992A (zh) * | 2022-11-08 | 2025-06-03 | 三养控股公司 | 阳离子脂质及其制备方法 |
| WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| WO2024226779A1 (en) * | 2023-04-26 | 2024-10-31 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025043146A2 (en) * | 2023-08-24 | 2025-02-27 | Molecular Axiom Inc. | Lipid nanoparticle compositions and methods of using same |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| FR3155424A1 (fr) | 2023-11-15 | 2025-05-23 | BioNTech SE | Compositions immunogènes contre le sars-cov-2 |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025166238A1 (en) * | 2024-01-31 | 2025-08-07 | Orna Therapeutics, Inc. | Fast-shedding polyethylene glycol lipids |
| WO2025178465A1 (ko) * | 2024-02-19 | 2025-08-28 | 주식회사 메디치바이오 | 신규한 이온화 지질 및 이를 이용한 지질 나노입자 조성물 |
| WO2025230906A1 (en) * | 2024-04-29 | 2025-11-06 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| WO2025237830A1 (en) * | 2024-05-15 | 2025-11-20 | Evonik Operations Gmbh | Polyoxyalkylene-1,2-di(alkyloxy)propanoxy-carbonylaminopropyl compounds, wherein the polyoxyalkylene is a poly(ethylene oxide) having c1 to c3-alkyloxymethyl side chains |
| WO2025255027A1 (en) * | 2024-06-03 | 2025-12-11 | Flagship Labs 114, Inc. | Lipid nanoparticles for topical delivery |
| WO2026047603A1 (en) | 2024-08-28 | 2026-03-05 | BioNTech SE | Sars-cov-2 immunogenic compositions |
| WO2026057625A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having a chap domain with engineered active site |
| WO2026057626A1 (en) | 2024-09-11 | 2026-03-19 | BioNTech SE | Peptidoglycan hydrolases having multiple enzymatically active domains |
| WO2026068864A1 (en) | 2024-09-30 | 2026-04-02 | BioNTech SE | Engineered ch1 and cl domains for the prevention of chain mispairing |
| WO2026082899A2 (en) | 2024-10-16 | 2026-04-23 | BioNTech SE | Rna for preventing or treating tuberculosis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2689042A1 (en) * | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| WO2013073480A1 (ja) * | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| AU2013237874B2 (en) * | 2012-03-29 | 2018-01-18 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
| JP6948313B6 (ja) * | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| JP6875685B2 (ja) * | 2015-10-08 | 2021-05-26 | 日油株式会社 | Ｏ／ｗ型エマルション |
| WO2017189870A1 (en) * | 2016-04-27 | 2017-11-02 | Massachusetts Institute Of Technology | Stable nanoscale nucleic acid assemblies and methods thereof |
| US11583504B2 (en) * | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| KR102696307B1 (ko) * | 2017-09-08 | 2024-08-16 | 제너레이션 바이오 컴퍼니 | 비-바이러스성 캡시드-비함유 dna 벡터의 지질 나노입자 제형 |
| CN111902397B (zh) * | 2018-03-27 | 2024-04-12 | 日油株式会社 | 改进了细胞内动力学的阳离子脂质 |
| WO2021046265A1 (en) * | 2019-09-06 | 2021-03-11 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
| JP2023502576A (ja) * | 2019-11-22 | 2023-01-25 | ジェネレーション バイオ カンパニー | イオン化可能な脂質およびそれらのナノ粒子組成物 |
| JP7746280B2 (ja) * | 2020-03-27 | 2025-09-30 | ジェネレーション バイオ カンパニー | 新規脂質及びそれらのナノ粒子組成物 |
| IL298241A (en) * | 2020-05-18 | 2023-01-01 | Generation Bio Co | New lipids and their nanoparticle preparations |
-
2021
- 2021-07-16 AU AU2021307952A patent/AU2021307952A1/en active Pending
- 2021-07-16 KR KR1020237005643A patent/KR20230052895A/ko active Pending
- 2021-07-16 JP JP2023502945A patent/JP2023534043A/ja active Pending
- 2021-07-16 US US18/015,575 patent/US20230320993A1/en active Pending
- 2021-07-16 IL IL299896A patent/IL299896A/en unknown
- 2021-07-16 MX MX2023000806A patent/MX2023000806A/es unknown
- 2021-07-16 CN CN202180063144.XA patent/CN116437964A/zh active Pending
- 2021-07-16 EP EP21842533.8A patent/EP4181948A4/en active Pending
- 2021-07-16 CA CA3186033A patent/CA3186033A1/en active Pending
- 2021-07-16 WO PCT/US2021/042033 patent/WO2022016089A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3186033A1 (en) | 2022-01-20 |
| CN116437964A (zh) | 2023-07-14 |
| AU2021307952A1 (en) | 2023-03-02 |
| WO2022016089A3 (en) | 2022-03-03 |
| US20230320993A1 (en) | 2023-10-12 |
| EP4181948A4 (en) | 2024-12-04 |
| WO2022016089A2 (en) | 2022-01-20 |
| KR20230052895A (ko) | 2023-04-20 |
| JP2023534043A (ja) | 2023-08-07 |
| MX2023000806A (es) | 2023-04-11 |
| EP4181948A2 (en) | 2023-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299896A (en) | Methods for thermoforming polynucleotides into reduced sizes of lipid nanoparticles and their new formulation | |
| GB2629329B (en) | Formulation comprising GalNAc-lipid nanoparticle | |
| IL296763B2 (en) | New lipids and their nanoparticle compositions | |
| GB2564793B (en) | A pharmaceutical formulation of palbociclib and a preparation method thereof | |
| SG10201701281VA (en) | Semiconductor device and method of forming emi shielding layer withconductive material around semiconductor die | |
| SG10201601155UA (en) | Semiconductor device and method of forming build-up interconnectstructures over carrier for testing at interim stages | |
| SG10201407250QA (en) | Semiconductor device and method of forming fine pitch rdl over semiconductor die in fan-out package | |
| TW201613562A (en) | Formulation comprising particles | |
| HUE050830T2 (hu) | Sztatinok és omega-3 zsírsavak gyógyászati kiszerelése kapszulázáshoz | |
| ZA201708429B (en) | Oral solid formulation containing irinotecan and method of preparing the same | |
| GB202000951D0 (en) | Semiconductor device and method of manufacture | |
| ZA202204050B (en) | Test method of particle size and particle size distribution of epristeride drug substance | |
| SG10201700762PA (en) | Semiconductor package and method of manufacturing semiconductor package | |
| WO2016100228A3 (en) | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids | |
| GB2562918B (en) | Semiconductor device and method of manufacturing semiconductor device | |
| GB2482713B (en) | Packaging apparatus including rotary jaw device and method of making packages | |
| HK40094398A (en) | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof | |
| SG10201601865XA (en) | Semiconductor device and method of manufacture | |
| IL282000A (en) | Device and method for the production and encapsulation of small particles and thin threads | |
| EP3381467A4 (en) | PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING A PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION | |
| EP3307294A4 (en) | Pharmaceutical composition for treatment of depression and preparation method thereof | |
| EP3979319A4 (en) | Semiconductor device and method for manufacture of semiconductor device | |
| HK40096297A (en) | Improved process and formulation of lipid nanoparticles | |
| PL3222279T3 (pl) | Doustny preparat farmaceutyczny montelukastu i lewocetyryzyny oraz sposób jego wytwarzania | |
| EP4199108B8 (en) | Semiconductor device and method of manufacturing semiconductor device |